AVITA Medical

AVITA Medical (NASDAQ: RCEL, ASX:AVH) is a leading therapeutic acute wound care company delivering transformative solutions.

Our technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering a groundbreaking so

lution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm®, a biosynthetic wound matrix. In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns and full-thickness skin defects. The RECELL System, excluding RECELL GO®, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.

05/29/2026

Don't miss a new educational RECELL™ webinar for our international audiences! RECELL in Practice: Clinical Perspectives on Healing, Function, and Appearance

Jonathan Schoen, MD, MPH, FACS, FABA, will share his clinical experience using RECELL, and the healing impact of Spray-On Skin™ Cells to treat acute wounds.

Date:
June 9, 2026

Time:
17:00 British Summer Time (BST)
18:00 Central European Standard Time (CEST)
19:00 Eastern European Summer Time (EEST)

Location:
Zoom webinar

Register now: https://na2.hubs.ly/H05LfB50

This webinar is intended for markets outside the United States.

05/28/2026

The AVITA Medical acute wound care portfolio was designed to help clinicians address healing through the entire wound care continuum:

✅ PermeaDerm® biosynthetic wound matrix for temporary wound coverage prior to excision
✅ Cohealyx® collagen dermal matrix to prepare a wound for closure
✅ RECELL® Spray-On Skin™ Cells for wound bed re-epithelialization with or without a skin graft

View the Acute Wound Treatment Algorithm guide to inform your surgical protocols of when and why to use each product: https://na2.hubs.ly/H05L3BL0

05/27/2026

A new study in the Journal of Burn Care & Research reports the first published use of NexoBrid® followed by RECELL® for friction injuries—an injury type that often results in an uneven wound bed with embedded debris, and could benefit from dermal preservation and epidermal regeneration technologies.

In this 13-patient case series, the combination supported outpatient management and avoidance of grafting while contributing to rapid healing and good cosmetic and functional outcomes. These findings highlight how enzymatic debridement followed by RECELL may offer a synergistic approach.

Read the study here: https://na2.hubs.ly/H05L1Gf0

05/26/2026

A new case report in Plastic and Reconstructive Surgery Global Open describes the use of split-thickness skin grafting (STSG) with RECELL® to reconstruct extensive ulcers in a patient with chronic granulomatous disease, a rare immune disorder associated with recurrent infections and poor wound healing.

Following months of failed conservative wound care, operative management including meshed STSG + RECELL resulted in near-total graft survival by postoperative day 5 and near-complete healing by 8 weeks. This report offers important clinical insight into how STSG + RECELL may help overcome refractory wounds and reduce donor-site morbidity in immune compromised patients.

05/25/2026

This Memorial Day, we pause to honor and remember the brave men and women who made the ultimate sacrifice in service to our country. Their courage and commitment have helped preserve the freedoms we value every day.

As we spend time with family and community, we reflect with gratitude on those who are no longer with us. We remember their service, their sacrifice, and the legacy they leave behind.

05/22/2026

View a clinical case of a 91-year-old female with full-thickness Morel-Lavallee lesion (internal degloving injury). Cohealyx® collagen dermal matrix was used to prepare the wound bed for grafting.

Despite several challenging co-morbidities and disruptions in negative pressure wound therapy care, Cohealyx exhibited early integration at day 5, with full integration at day 15. This case highlights the ability of Cohealyx to support robust wound bed preparation in complex patients.

See the full clinical case with wound progression images here: https://na2.hubs.ly/H05DWj40

05/21/2026

Cohealyx® is a collagen dermal matrix designed to support early graft-readiness. At last month's American Burn Association (ABA) 2026 Annual Meeting, AVITA Medical presented interim analysis results from the ongoing Cohealyx-I clinical trial in patients with full-thickness wounds (https://na2.hubs.ly/H05DXdN0 ID NCT06787690).

In this multicenter study, patients managed with Cohealyx achieved graft-readiness over 50% sooner compared to a literature-derived benchmark. Notably, median time to graft-readiness with Cohealyx was 11 days, with some patients graft-ready as early as 5 days. These findings showcase how Cohealyx supports timely graft-readiness and highlights its potential in advancing reconstructive wound care.

Read more on the exciting findings here: https://na2.hubs.ly/H05DXp00

05/20/2026

Clinical Trials Day is celebrated globally each May 20. Today we recognize the patients, clinicians, researchers, and study teams who make medical innovation possible. A special thank you to our clinical research team and clinical education specialists for their dedication, expertise, and commitment to advancing patient care every day.

05/19/2026

A new case report in the Journal of Burn Care & Research describes the use of PermeaDerm® to support healing of a radiation-induced neck wound following chemoradiation in an 86-year-old man.

Radiation and chemotherapy can impair re-epithelialization and delay wound healing, making these injuries challenging to manage. In this case, PermeaDerm was associated with reduced pain and remained in place through near-complete healing by day 5, with complete re-epithelialization observed by day 6.

This case highlights the versatility of PermeaDerm, an adherent biosynthetic wound matrix used for temporary wound coverage prior to grafting, to be useful for managing radiation-induced skin injuries while reducing the need for dressing changes.

Read it here: https://na2.hubs.ly/H05DcpD0

05/15/2026

Allograft for temporary wound coverage after excision can be a logistical challenge. PermeaDerm® is gaining increasing clinical attention as a dependable alternative option, particularly when clinicians need something that’s readily available and straightforward to apply. Read more in a new Wound Healing Insights article.

Read it here: https://na2.hubs.ly/H05v8_x0

Address

28159 Avenue Stanford
Valencia, CA
91355

Website

https://avitamedical.com/, https://ir.avitamedical.com/

Alerts

Be the first to know and let us send you an email when AVITA Medical posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your business to be the top-listed Engineering Company in Valencia?